Related Experiment Video

Updated: Apr 19, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.3K

Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive

Donatella Gambini1, Elisa Locatelli2, Umberto Gianelli3

  • 1Unit of Medical Oncology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy gambini.donatella@policlinico.mi.it.

Anticancer Research
|December 16, 2014
PubMed
Abstract

Insights

Neuroendocrine markers in primary renal cell carcinoma may predict response to sunitinib treatment. This finding could guide therapy selection for metastatic renal cell carcinoma, optimizing patient outcomes.

Area of Science:

  • Oncology
  • Molecular Pathology

Background:

  • Metastatic renal cell carcinoma (mRCC) lacks recognized predictive factors for treatment selection.
  • Optimizing mRCC therapy is crucial due to significant side-effects and costs.

Observation:

  • A case of complete remission in mRCC after 1 year of sunitinib treatment is reported.
  • Pancreatic metastases were detected via 68Ga-DOTA-NOC positron emission tomography (PET).
  • Histological revision and immunohistochemical staining of the primary tumor revealed neuroendocrine markers.

Findings:

  • Detection of neuroendocrine markers in the primary tumor.
  • Positive 68Ga-DOTA-NOC PET findings in pancreatic metastases.

Implications:

  • Neuroendocrine markers may serve as predictive indicators for sunitinib response in mRCC.
  • This discovery could personalize targeted therapy selection for renal cell carcinoma.
  • Further research is warranted to validate these potential predictive biomarkers.
Keywords:
Neuroendocrine markerspredictive markersrenal cell carcinomasunitinib

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.5K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
790
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K